Incorporation of tumor vasculature targeting motifs into moloney murine leukemia virus Env escort proteins enhances retrovirus binding and transduction of human endothelial cells

Journal of Virology

Volumn 74, Issue 11, 2000, Pages 5320-5328

  Liu, Liqiong ^a   Liu, Ling ^a   Anderson, W French ^a,b   Beart, Robert W ^b   Gordon, Erlinda M ^a,b   Hall, Frederick L ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRONECTIN; RECEPTOR; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ANIMAL CELL; ARTICLE; CELL ADHESION; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE TARGETING; HUMAN; HUMAN CELL; MOLONEY LEUKEMIA ONCOVIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; TUMOR VASCULARIZATION; VIRION;

3T3 CELLS; ANIMALS; BASE SEQUENCE; BINDING SITES; CELL LINE, TRANSFORMED; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; FIBRONECTINS; GENE EXPRESSION; GENE PRODUCTS, ENV; GENETIC VECTORS; HUMANS; LYMPHOKINES; MICE; MOLECULAR SEQUENCE DATA; MOLONEY MURINE LEUKEMIA VIRUS; NEOPLASMS; RETROVIRIDAE PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034068116     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.11.5320-5328.2000     Document Type: Article

References (64)

1. Adams, J. C., and F. M. Watt. 1993. Regulation of development and differentiation by the extracellular matrix. Development 117:1183-1198.
2. Anderson, W. F. 1995. Gene therapy. Sci. Am. 273:124-128.
3. Anderson, W. F. 1998. Human gene therapy. Nature 392:25-33.
4. Aota, S., T. Nagai, and K. M. Yamada. 1991. Characterization of regions of fibronectin besides the arginine-glycine-aspartic acid sequence required for adhesive function of the cell-binding domain using site-directed mutagenesis. J. Biol. Chem. 266:15938-15943.
5. Arap, W., R. Pasquilani, and E. Ruoslahti. 1998. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279: 377-380.
6. Ayad, S., R. P. Boot-Handford, M. J. Humphries, K. E. Kadler, and C. A. Shuttleworth. 1998. The extracellular proteins, p. 149-152. In The extracellular matrix facts book, section II, 2nd ed. (Academic Press. Harcourt Brace & Co., Publishers, San Diego. Calif.).
7. Bergers, G., K. Javaherian, K. M. Lo, J. Folkman, and D. Hanahan. 1999. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 248:808-812.
8. Brekken, R. A., X. Huang, S. W. King, and P. E. Thorpe. 1998. Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res. 58:1952-1959.
9. Brogi, E., G. Schatteman, T. Wu, E. A. Kim, L. Varticovski, B. Keyt, J. M. Isner. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. J. Clin. Investig. 97:469-476.
10. 3, antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157-1164.
11. Burrows, F. J., and P. E. Thorpe. 1994. Vascular targeting: a new approach to the therapy of solid tumors. Pharmacol. Ther. 64:155-174.
12. Claffey, K. P., L. F. Brown, L. F. del Aguila, K. Tognazzi, K. T. Yeo, E. J. Manseau, and H. F. Dvorak. 1996. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res. 56:172-181.
13. Connolly, D. T., D. M. Heuvelman, R. Nelson, J. V. Olander, B. L. Eppley, J. J. Delfino, N. R. Siegel, R. M. Leimgruber, and J. Feder. 1989. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J. Clin. Investig. 84:1470-1478.
14. Cosset, F. L., F. J. Morling, U. Takeuchi, R. A. Weiss, M. K. Collins, and S. J. Russell. 1995. Retroviral retargeting by envelopes expressing an N-terminal binding domain. J. Virol. 69:6314-22.
15. Dvorak, H. F., J. A. Nagy, and A. M. Dvorak. 1991. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells 3:77-85.
16. Dvorak, H. F., L. F. Brown, M. Detmar, and A. M. Dvorak. 1995. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146:1029-1039.
17. Evans, L. H., F. G. Morrison, J. Malik, J. Portis, and W. J. Britt. 1990. A neutralizable epitope common to the envelope glycoprotein of ecotropic, polytropic, xenotropic. and amphotropic murine leukemia viruses. J. Virol. 64:6176-6183.
18. Fidler, I. J. 1995. Modulation of the organ microenvironment for treatment of cancer metastasis. J. Natl. Cancer Inst. 87:1588-1592.
19. Folkman, J. 1998. Antiangiogenic gene therapy. Proc. Natl. Acad. Sci. USA 95:9064-9066.
20. Forsythe, J. A., B. H. Jiang, N. V. Iyer, F. Agani, S. W. Leung, R. D. Koos, and G. L. Semenza. 1996. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducihle factor I. Mol. Cell Biol. 16:4604-4613.
21. Friedlander, M., P. C. Brooks, R. W. Shaffer, C. M. Kincaid, J. A. Varner, and D. A. Cheresh. 1995. Definition of two angiogenic pathways by distinct alpha v integrins. Science 270:1500-1502.
22. Fukumura, D., R. Xavier, T. Sugiura, Y. Chen, E. Park, N. Lu, M. Selig, G. Neilsen, T. Taksir, R. K. Jain, and B. Seed. 1998. Tumor with VEGF promoter activity in stromal cells. Cell 94:715-725.
23. Griscelli, F., H. Li, A. Bennaceur-Griscelli, J. Soria, P. Opolon, C. Soria, M. Perricaudet, P. Yeh, and H. Lu. 1998. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with mitosis arrest. Proc. Natl. Acad. Sci. USA 95:6367-6372.
24. Gurrath, M., G. Muller, H. Kessler, M. Aumailley, and R. Timpl. 1992. Conformation activity studies of rationally designed potent anti-adhesive RGD peptides. Eur. J. Biochem. 210:911-921.
25. Hall, F. L., E. M. Gordon, L. Wu, N. L. Zhu, M. J. Skotzko, V. A. Starnes, and W. F. Anderson. 1997. Targeting retroviral vectors to vascular lesions by genetic engineering of the MoMuLV gp70 envelope protein. Hum. Gene Ther. 8:2183-2192.
26. Hammes, H. P., M. Brownlee, A. Jonczyk, A. Sutter, and K. T. Preissner. 1996. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat. Med. 2:529-533.
27. Hanahan, D., and J. Folkman. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364.
28. Hanenberg, H., X. L. Xiao, D. Dilloo, K. Hashino, I. Kato, and D. A. Williams. 1996. Colocalizalion of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat. Med. 2:876-882.
29. Healy, J. M., O. Murayama, T. Maeda, K. Yoshino, K. Sekiguchi, and M. Kikuchi. 1995. Peptide ligands for integrin αvβ3 selected from random phage display libraries. Biochemistry 34:3948-3955.
30. Humphries, M. J., A. Komoriya, S. K. Akiyama, K. Olden, and K. M. Yamada. 1987. Identification of two distinct regions of the type III connecting segment of human plasma fibronectin that promote cell type-specific adhesion. J. Biol. Chem. 262:6886-6892.
31. Johnson, R. C., D. Zhu, H. G. Augustin-Voss, and B. V. Pauli. 1993. Lung endothelial dipeptidyl peptidase IV is an adhesion molecule for lung-metastatic rat breast and prostate carcinoma cells. J. Cell Biol. 121:1423-1432.
32. Keck, P. J., S. D. Hauser, G. Krivi, K. Sanzo, T. Warren, J. Feder, and D. T. Connolly. 1989. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246:1309-1312.
33. Ke-Lin, Q. H., J. A. Nagy, I. A. Eckelhoefer, E. M. Masse, A. M. Dvorak, and H. F. Dvorak. 1996. Vascular targeting of solid and ascites tumours with antibodies to vascular endothelial growth factor. Eur. J. Cancer 32A:2467-2473.
34. Koivunen, E., D. A. Gay, and E. Ruoslahti. 1993. Selection of peptides to the α5β1 integrin from phage display library. J. Biol. Chem. 268:20205-20210.
35. Koivunen, E., B. Wang, and E. Ruoslahti. 1994. Isolation of a highly specific ligand for the α5β1 integrin from a phage display library. J. Cell Biol. 124:373-379.
36. Koivunen, E., B. Wang, and E. Ruoslahti. 1995. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Bio/Technology 13:265-270.
37. Kornblihtt, A. R., K. Umezawa, K. Vibe-Pederson, and F. E. Barelle. 1985. Primary structure of human fibronectin: differential splicing may generate at least 10 polypeptides from a single gene. EMBO J. 4:1755-1759.
38. Lin, C. Q, and M. J. Bissell. 1993. Multi-faceted regulation of cell differentiation by extracellular matrix. FASEB J. 7:737-743.
39. Masood, R., J. Cai, T. Zheng, D. L. Smith, Y. Naidu, and P. S. Gill. 1997. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc. Natl. Acad. Sci. USA 94:979-984.
40. Mazure, N. M., E. Y. Chen, P. Yeh, K. R. Laderoute, and A. J. Giaccia. 1996. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res. 56:3436-3440.
41. Mohri, H. 1996. Fibronectin and integrins interactions. J. Investig. Med. 44:429-438.
42. Nagai, T., N. Yamakawa, S. Aota, S. S. Yamada, S. K. Akiyama, K. Olden, and K. M. Yamada. 1991. Monoclonal antibody characterization of two distinct sites required for function of the central cell-binding domain of fibronectin in cell adhesion, cell migration, and matrix assembly. J. Cell Biol. 114:1295-1305.
43. Obara, M., M. S. Kang, and K. M. Yamada. 1988. Synthetic peptides competitively inhibit both direct binding to fibroblasts and functional biological assays for the purified cell-binding domain of human fibronectin: separable, synergistic sites mediate adhesive function. Cell 53:649-657.
44. O'Neil, K. T., R. H. Hoess, S. A. Jackson, N. S. Ramachandran, S. A. Mousa, and W. F. DeGrado. 1992. Identification of novel peptide antagonists for GPIIb/IIa from a conformationally constrained phage peptide library. Proteins 14:509-515.
45. Pasqualini, R., and E. Ruoslahti. 1996. Organ targeting in vivo using phage display peptide libraries. Nature 380:364-366.
46. Pepper, M. S., and S. J. Mandriota. 1998. Regulation of vascular endothelial growth factor receptor-2 (Flk-1) expression in vascular endothelial cells. Exp. Cell Res. 241:414-425.
47. Pfaff, M., K. Tangemann, B. Muller, M. Gurrath, G. Muller, H. Kessler, R. Timpl, and J. Engel. 1994. Selective recognition of cyclic RGD peptides of NMR defined conformation by αIIβ3, αVβ3, and α5β1 integrins. J. Biol. Chem. 269:20233-20238.
48. Pierschbacher, M. D., and E. Ruoslahti. 1984. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 309:30-33.
49. Piersbacher, M. D., and E. Ruoslahti. 1987. Influence of stereochemistry of the sequence Arg-Gly-Asp-Xa on binding specificity in cell adhesion. J. Biol. Chem. 262:17294-17298.
50. Plate, K. H., G. Breier, H. A. Weich, H. D. Mennel, and W. Risau. 1994. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int. J. Cancer 59:520-529.
51. Ruoslahti, E., and M. D. Pierschbacher. 1986. Arg-Gly-Asp: a versatile cell recognition signal. Cell 44:5985-5988.
52. Senger, D. R., S. J. Galli, A. M. Dvorak, C. A. Perruzzi, V. S. Harvey, and H. F. Dvorak. 1983. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985.
53. Senger, D. R., C. A. Perruzzi, J. Feder, and H. F. Dvorak. 1986. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res. 46:5629-5632.
54. Skorstengaard, K., M. S. Jensen, O. Sahl, T. E. Petersen, and S. Magnusson. 1986. Purification of a complete primary structure of the heparin-, cell-, and DNA-binding domain of bovine plasma fibronectin. Eur. J. Biochem. 161: 441-153.
55. Skotzko, M., L. Wu, W. F. Anderson, E. M. Gordon, and F. L. Hall. 1995. Retroviral Vector-mediated gene transfer of antisense cyclin G1 (CYCG1) inhibits proliferation of human osteogenic sarcoma cells. Cancer Res. 55: 5493-5498.
56. Soneoka, Y., P. M. Cannon, E. E. Ramsdale, J. C. Griffiths, R. Gaetano, S. M. Kingsman, and A. J. Kingsman. 1995. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res. 23:628-633.
57. Stromblad, S., and D. A. Cheresh. 1996. Cell adhesion and angiogenesis. Trends Cell Biol. 6:462-466.
58. Tanaka, T., Y. Cao, J. Folkman, and H. A. Fine. 1998. Viral vector-targeted antiagniogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res. 58:3362-3369.
59. Thomas, K. A. 1996. Vascular endothelial growth factor, a potent and selective angiogenic agent. J. Biol. Chem. 271:602-606.
60. Vulliet, P. R., F. L. Hall, J. P. Mitchell, and D. G. Hardie. 1988. A novel growth factor-sensitive protein kinase in pheochromocytoma. Proc. West. Pharmacol. Soc. 31:255-258.
61. Waltenberger, J., U. Mayr, S. Pentz, and V. Hombach. 1996. Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia. Circulation 94:1647-1654.
62. Wu, B. W., P. M. Cannon, E. M. Gordon, F. L. Hall, and W. F. Anderson. 1998. Characterization of the proline-rich region of murine leukemia virus envelope protein. J. Virol. 72:5383-5391.
63. Zhao, Y., S. Lee, and W. F. Anderson. 1997. Functional interactions between monomers of the retroviral envelope protein complex. J. Virol. 71:6967-6972.
64. Zhu, N. L., P. M. Cannon, D. Chen, and W. F. Anderson. 1998. Mutational analysis of the fusion peptide of Moloney murine leukemia virus transmembrane protein pl5E. J. Virol. 72:1632-1639.